Increased Soluble CD155 in the Serum of Cancer Patients

• Published in: PLoS ONE Vol. 11; no. 4; p. e0152982
• Main Authors: 坂東 裕子, 井口 研子, 小島 寛, 佐藤 豊実, 原 尚人, 渋谷 彰, 渋谷 和子, Yoshikawa Hiroyuki, Okumura Genki, Cho Yukiko, Hirochika Rei, Iguchi-Manaka Akiko, Bando Hiroko, Kojima Hiroshi, Sato Toyomi, Hara Hisato, Shibuya Akira, Shibuya Kazuko
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.04.2016; Public Library of Science (PLoS)
• Subjects: Aged; Animal tissues; Animals; Bioindicators; Biology and Life Sciences; Biomarkers; Biomarkers, Tumor - blood; Cancer; Cancer patients; Care and treatment; Case-Control Studies; CD226 antigen; Cytotoxicity; Gastric cancer; Gene expression; Gynecology; Health aspects; Hospitals; Human tissues; Humans; Immunity; Immunoglobulins; Immunology; Isoforms; Killer Cells, Natural - immunology; Leukemia; Ligands; Lungs; Lymphocytes; Lymphocytes T; Lysis; Medical research; Medicine; Medicine and Health Sciences; Melanoma; Mice; Middle Aged; Natural killer cells; Neoplasms - blood; Neoplasms - pathology; Obstetrics; Patients; Physiological aspects; Proteins; R&D; Receptors, Virus - blood; Research & development; Research and Analysis Methods; Surgery; T cells; T-Lymphocytes, Cytotoxic - immunology; Tumor cells; Tumors; United States > US; Japan; Baltimore Maryland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0152982

Emerging evidence suggests that DNAM-1 (CD226) play an important role in the recognition of tumor cells and their lysis by cytotoxic T lymphocytes (CTL) and NK cells. Although the DNAM-1 ligand CD155 is ubiquitously expressed in various tissues, many human tumors significantly upregulate the expression of CD155; DNAM-1 on CTL and NK cells may be involved in tumor immunity. However, unlike those in mice, human tissues also express soluble isoforms of CD155 (sCD155) that lack the transmembrane region. Here, we show that sCD155 levels were significantly higher in the sera of 262 patients with lung, gastrointestinal, breast, and gynecologic cancers than in sera from healthy donors. In addition, the sCD155 levels were significantly higher in patients with early stage (stages 1 and 2) gastric cancer than in healthy donors, and were significantly higher in patients with\nadvanced stage (stages 3 and 4) disease than in patients in those with early stage disease and healthy donors. Moreover, the sCD155 levels were significantly decreased after surgical resection of cancers. Thus, sCD155 level in serum may be potentially useful as a biomarker\nfor cancer development and progression.